公开(公告)号：EP1268528A2

公开(公告)日：2003-01-02

申请号：EP01962418.8

申请日：2001-03-27

申请人： Chiron Corporation ,  Hyseq Inc.

发明人： WILLIAMS, Lewis T. ,  ESCOBEDO, Jaime ,  INNIS, Michael A. ,  GARCIA, Pablo Dominguez ,  SUDDUTH-KLINGER, Julie ,  REINHARD, Christoph ,  HE, Zhijun ,  RANDAZZO, Filippo ,  KENNEDY, Giulia C. ,  POT, David ,  KASSAM, Altaf ,  LAMSON, George ,  DRMANAC, Radoje ,  CRKVENJAKOV, Radomir ,  DICKSON, Mark ,  DRMANAC, Snezana ,  LABAT, Ivan ,  LESHKOWITZ, Dena ,  KITA, David ,  GARCIA, Veronica ,  JONES, Lee William ,  STACHE-CRAIN, Birgit

IPC分类号： C07K14/00

CPC分类号： C07K14/47

摘要： This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variant thereof, to genes corresponding to theses polynucleotides and to proteins expressed by the genes. This invention also relates to diagnostic and therapeutic agents employing such novel polynucleotides, their corresponding genes or gene products, ∫i⊃e.g.∫/i⊃, these genes and proteins, including probes, antisense constructs, and antibodies.

摘要翻译： 本发明涉及对应于这些多核苷酸的基因和由该基因表达的蛋白质的新型人多核苷酸及其变体，其编码的多肽及其变体。 本发明还涉及使用这种新型人多核苷酸的诊断和治疗剂，其相应的基因或基因产物，例如这些基因和蛋白质，包括探针，反义构建体和抗体。

公开(公告)号：EP1265476A2

公开(公告)日：2002-12-18

申请号：EP00989407.2

申请日：2000-12-21

申请人： PIONEER HI-BRED INTERNATIONAL, INC.

发明人： JANSEN, Ritsert, C. ,  BEAVIS, William, D.

IPC分类号： A01H1/04 ,  A01H5/00 ,  C12Q1/68

CPC分类号： C12N15/8241 ,  A01H1/04 ,  G06F19/18

摘要： Methods for mapping a phenotypic trait to a corresponding chromosomal location are provided. Statistical methods which correlate pedigrees with multiple genetic markers, the haplotype, to determine identical-by-descent (IBD) data are employed to map phenotypic traits. The statistical models provided are a HAPLO-IM+ model, a HAPLO-MQM model, and a HAPLO-MQM+ model. These statistical methods are applied to map traits determined alternatively by single genes or by quantitative trait loci. Methods of marker assisted selection (MAS) using a variety of genetic markers are provided. Plants selected by MAS using the methods are provided. Additionally, methods for cloning nucleic acids corresponding to phenotypic traits that are in linkage disequilibrium with genetic markers are provided, and for transducing them into plant cells are provided. Transgenic plants transduced with the cloned nucleic acids corresponding to phenotypic traits, e.g. QTL, are provided.

公开(公告)号：EP1260520A2

公开(公告)日：2002-11-27

申请号：EP02006768.2

申请日：1996-12-17

申请人： MYRIAD GENETICS, INC. ,  Endo Recherche Inc. ,  THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ,  HSC Research and Development Limited Partnership

发明人： Tavtigian, Sean V. ,  Kamb, Alexander ,  Simard, Jacques ,  Couch, Fergus ,  Rommens, Johanna M. ,  Weber, Barbara L.

IPC分类号： C07K14/82 ,  C12Q1/68 ,  G01N33/53 ,  A01K67/027

CPC分类号： C07K14/4703 ,  A61K48/00 ,  Y10S530/828

摘要： The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA2 gene for mutations, which are useful for diagnosing the predisposition to breast cancer.

摘要翻译： 本发明一般涉及人类遗传学领域。 具体而言，本发明涉及用于分离和检测人乳腺癌易感基因（BRCA2）的方法和材料，其中一些突变等位基因引起对癌症尤其是乳腺癌的易感性。 更具体地说，本发明涉及BRCA2基因中的种系突变及其在诊断乳腺癌易感性中的用途。 本发明进一步涉及人乳腺癌中BRCA2基因的体细胞突变及其在人乳腺癌的诊断和预后中的用途。 此外，本发明涉及其他人类癌症中BRCA2基因的体细胞突变及其在人类癌症的诊断和预后中的用途。 本发明还涉及在BRCA2基因中具有突变的人类癌症的治疗，包括基因治疗，蛋白质替代疗法和蛋白质模拟物。 本发明还涉及用于癌症治疗的药物的筛选。 最后，本发明涉及BRCA2基因突变的筛选，其可用于诊断乳腺癌倾向。

公开(公告)号：EP1254263A2

公开(公告)日：2002-11-06

申请号：EP01904171.4

申请日：2001-02-09

申请人： Pharma Pacific Pty. Ltd.

发明人： MERITET, Jean-François ,  DRON, Michel ,  TOVEY, Michael, Gérard

IPC分类号： C12Q1/68

CPC分类号： G01N33/6866 ,  G01N2333/56 ,  G01N2800/52

摘要： The present disclosure relates to identification of previously known genes as being genes upregulated by interferon-α administration, in particular the human genes corresponding to the cDNA sequence in GenBank designated g4758303, g5453897, g4505186, g2366751, g33917, g4504962, g3978516, g5924396, g4505656, g1504007, g3702446, g4001802, g292289, g4557226, g4507646 and g4507170. Determination of expression products of these genes is proposed as having utility in predicting responsiveness to treatment with interferon-α and other interferons which act at the Type 1 interferon receptor.

公开(公告)号：EP1251873A1

公开(公告)日：2002-10-30

申请号：EP01946791.9

申请日：2001-01-25

申请人： Pharma Pacific Pty. Ltd.

发明人： TOVEY, Michael, Gerard

IPC分类号： A61K39/395 ,  C07K14/715 ,  A61K9/00 ,  A61P37/06 ,  A61K38/17

CPC分类号： A61K9/0043 ,  A61K38/1793 ,  A61K2039/505 ,  C07K16/249

摘要： Oromucosal administration of antagonists of cytokines associated with stimulation or enhancement of T helper 1 cell responses, preferably for example a Type 1-interferon antibody, is disclosed for inhibition of prevention of autoimmune diseases.

公开(公告)号：EP1244788A2

公开(公告)日：2002-10-02

申请号：EP01900925.7

申请日：2001-01-05

申请人： PIONEER HI-BRED INTERNATIONAL, INC.

发明人： MAHAJAN, Pramond, B.

IPC分类号： C12N15/29 ,  C12N15/82 ,  C12N9/24 ,  A01H5/00

CPC分类号： C12N15/8201 ,  C07K14/415

摘要： The invention provides isolated mutM nucleic acids and their encoded proteins. The present invention provides methods and compositions relating to altering maize mutM levels in plants in order to improve transformation efficiency, homologous recombination and/or targeted gene modifications. The invention further provides recombinant expression cassettes, host cells, transgenic plants, and antibody compositions.

摘要翻译： 本发明提供编码具有8-氧基鸟嘌呤DNA糖基化酶（OGG）活性的多肽的分离的多核苷酸。 本发明提供了与植物中表达OGG相关的方法和组合物，以便提高转化效率，同源重组和/或靶向基因修饰。 本发明还提供重组表达盒，宿主细胞，转基因植物和抗体组合物。

公开(公告)号：EP1234174A1

公开(公告)日：2002-08-28

申请号：EP00982312.1

申请日：2000-12-01

申请人： MYRIAD GENETICS, INC.

发明人： HEICHMAN, Karen ,  CIMBORA, Daniel, M. ,  BUSH, Angie ,  BARTEL, Paul, L.

IPC分类号： G01N33/00 ,  A01K67/00 ,  A01K67/027 ,  A01K67/033 ,  C12N15/00 ,  C12N15/02 ,  C12N15/09 ,  C12N15/63 ,  C12N15/70 ,  C12N15/74 ,  C07K1/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00

CPC分类号： C12N9/1205 ,  A01K2217/05 ,  C07K16/00

摘要： The present invention relates to the discovery of novel protein-protein interactions that are involved in mammalian physiological pathways, including physiological disorders or diseases. Examples of physiological disorders and diseases include non-insulin dependent diabetes mellitus (NIDDM), neurodegenerative disorders, such as Alzheimer's Disease (AD), and the like. Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of physiological generative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.

公开(公告)号：EP1226260A2

公开(公告)日：2002-07-31

申请号：EP00976948.0

申请日：2000-11-02

申请人： PIONEER HI-BRED INTERNATIONAL, INC.

发明人： HELENT JARIS, Timothy, G.

IPC分类号： C12N15/82 ,  C12N15/53 ,  C12N15/54 ,  C12N9/02 ,  C12N9/10 ,  C12N5/10 ,  A01H5/00

CPC分类号： C12N9/0071 ,  C12N9/0004 ,  C12N9/1007 ,  C12N15/8255

摘要： The present invention provides methods and compositions relating to altering lignin biosynthesis content and/or composition of plants. The invention provides isolated nucleic acids and their encoded proteins that are involved in lignin biosynthesis. The invention further provides recombinant expression cassettes, host cells, transgenic plants, and antibody compositions.

公开(公告)号：EP1218751A2

公开(公告)日：2002-07-03

申请号：EP00964460.0

申请日：2000-10-02

申请人： ISIS INNOVATION LIMITED

发明人： ANDERSON, Robert Paul,Molecular Immunology ,  HILL, Adrian Vivian Sinton,Wellcome Trust Centre ,  JEWELL, Derek Parry,Gastroenterology Unit

IPC分类号： G01N33/68 ,  C07K14/415 ,  A61P37/08

CPC分类号： C07K14/415 ,  A61K49/0006 ,  C12N15/8257 ,  C12N15/8258 ,  G01N33/505 ,  G01N33/564 ,  G01N33/6854 ,  G01N33/6863 ,  G01N33/6878 ,  G01N2333/9108 ,  Y10S435/975

摘要： A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: (a) contacting a sample from the host with an agent selected from (i) the epitope comprising sequence which is: SEQ ID NO: 1 or 2, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID N0:3, (ii) an epitope comprising sequence comprising: SEQ ID NO:1, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO:3, which epitope is an isolated oligopeptide derived from a gliadin protein, (iii) an analogue of (i) or (ii) which is capable of being recognised by a T cell receptor that recognises (i) or (ii), which in the case of a peptide analogue is not more than 50 amino acids in length, or (iv) a product comprising two or more agents as defined in (i), (ii) or (iii), and (b) determining in vitro whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease. Therapeutic compositions which comprise the epitope and gliadin proteins which do not cause coeliac disease are also provided.

摘要翻译： 在个体中诊断乳糜泻或对乳糜泻的易感性的方法，其包括：（a）使来自宿主的样品与选自以下的试剂接触：（i）包含SEQ ID NO：1或2的序列的表位， 或来自SEQ ID NO：3所示的麦醇溶蛋白的天然存在的同源物的等同序列，（ii）包含SEQ ID NO：1的序列的表位，或SEQ ID NO：1所示的麦醇溶蛋白的天然存在的同源物的等同序列 （i）或（ii）的类似物，所述类似物能够被识别（i）或（ii）的T细胞受体识别，其中所述表位是源自麦醇溶蛋白的分离的寡肽， ，其在肽类似物的情况下长度不超过50个氨基酸，或（iv）包含两种或更多种如（i），（ii）或（iii）中定义的试剂的产物，和（b） 在体外样品中的T细胞是否识别该试剂; T细胞识别，表明该个体患有乳糜泻或易患乳糜泻。 还提供了包含不引起腹腔疾病的表位和麦醇溶蛋白的治疗组合物。

公开(公告)号：EP1214435A2

公开(公告)日：2002-06-19

申请号：EP00963744.8

申请日：2000-09-22

申请人： PIONEER HI-BRED INTERNATIONAL, INC.

发明人： JIAO, Shuping ,  HABBEN, Jeffrey, E. ,  NIU, Xiaomu

IPC分类号： C12N15/82 ,  C07K14/415 ,  A01H5/00

CPC分类号： C12N15/8222 ,  C07K14/415 ,  C12N15/8234

摘要： The present invention provides a composition and method for regulating expression of heterologous nucleotide sequences in a plant. The composition is a novel nucleic acid sequence for a seed-preferred promoter. A method for expressing a heterologous nucleotide sequence in a plant using the promoter sequence is also provided. The method comprises transforming a plant cell to contain a heterologous nucleotide sequence operably linked to the seed-preferred promoter of the present invention and regenerating a stably transformed plant from the transformed plant cell.